Drug pric­ing re­form ex­pect­ed to be biggest drag on bio­phar­ma in 2020; Beam up­sizes IPO of­fer­ing

→ US Pres­i­dent Trump‘s State of the Union ad­dress may have vis­i­bly elicit­ed the ire of Speak­er Nan­cy Pelosi but he did em­pha­size again the need for bi­par­ti­san leg­is­la­tion to low­er drug prices. A sur­vey con­duct­ed by Glob­al­Da­ta showed that 49% of glob­al in­dus­try re­spon­dents be­lieve that drug pric­ing and re­im­burse­ment con­straints will have the great­est neg­a­tive im­pact on the phar­ma­ceu­ti­cal in­dus­try this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER